Hongbin Yi

Hongbin Yi

Auto-generated profile, based on publicly available information

Hongbin Yi

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Journal of Global Health
Verified
Journal Article
Open access
HYHongbin Yi
Hongbin Yi
MCMengtian Cai
Mengtian Cai
XWXiaoxia Wei
Xiaoxia Wei
YCYingdan Cao
Yingdan Cao
LKLiping Kuai
Liping Kuai
SHSheng Han
Sheng Han
Cancer is a global problem that lacks a global solution [1]. A study indicated that there were 19.3 million new cases of cancer and almost 10 million deaths from cancer in 2020. Cancer is a significant cause of morbidity and mortality worldwide, across all regions and at all levels of human development [2]. Harnessing the […]

18 October 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
HYHongbin Yi
Hongbin Yi
FSFenghao Shi
Fenghao Shi
ZWZihao Wang
Zihao Wang
LKLiping Kuai
Liping Kuai
DXDongyan Xu
Dongyan Xu
HXHua Xing
Hua Xing
Objective To evaluate the impacts of the 2017 adjustment of National Reimbursement Drug List (NRDL) on orphan drugs hospital procurement volumes and spending in China. Design We used an interrupted time series design covering the period from 2016 to 2018 to analyse changes in hospital procurement volumes and spending of orphan drugs for which were included in the 2017 NRDL. Setting and data The study was conducted in China. Orphan drug procurement data of 789 public hospitals (594 tertiary hospitals and 195 secondary hospitals) were derived from the Chinese Medical Economic Information (CMEI). Outcome measures Monthly orphan drugs hospital procurement volumes and spending. Results Nine orphan drugs were included in the 2017 NRDL (seven were directly included, and two were included after price negotiation). Comparing to orphan drugs not included in the NRDL, hospital procurement volumes ( =43 312, p<0.001) and spending ( =6 48 927, p<0.001) of the nine included drugs showed significant upward trends after implementation of the 2017 NRDL adjustment. Conclusions Our results suggest that the 2017 adjustment of NRDL significantly changed the usage and spending on certain orphan drugs. The increase in orphan drug hospital procurement volumes should improve rare disease patients’ access to these orphan drugs.



1 April 2026 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
HYHongbin Yi
Hongbin Yi
STShuhua Tan
Shuhua Tan
MCMengtian Cai
Mengtian Cai
LKLiping Kuai
Liping Kuai
DXDongyan Xu
Dongyan Xu
SHSheng Han
Sheng Han
Introduction: To alleviate the diabetes economic burden, the Chinese government implemented the national volume-based procurement (NVBP) policy exclusively for insulin in May 2022. However, there is limited evidence on the impact of NVBP policy on insulin procurement prices, volumes and expenditures. Methods: We conducted an interrupted time series analysis (ITSA) to evaluate the policy’s impacts on insulin procurement prices, volumes and expenditure. Quarterly data for 15 insulins were extracted from the China Medicine Economic Information database, covering 761 public hospitals in 30 provinces from Q3 2020 to Q4 2023. The intervention time of the ITSA model is Q2 2022. Insulin prices are measured using the defined daily dose (DDD) cost, while the volumes are measured using DDDs. Results: Following the NVBP implementation, all NVBP bid-winning insulin prices decreased by 51.61%, volume increased by 16.73% and expenditure decreased by 43.52%. All NVBP bid-winning insulin volumes increased by 9152.73 thousand DDDs and showed an upward trend (p<0.05). The expenditure decreased by 176.65 million Chinese yuan (CNY) (p<0.05). The prices of all six NVBP insulin groups decreased significantly, and the prices of the three NVBP insulin groups showed a downward trend (p<0.05). The volumes of all six NVBP insulin groups showed significant increases in either level or trend. Except for premixed human insulin analogues, expenditure significantly changed in level or trend in the remaining five groups (p<0.05). Individually, all 15 insulins exhibited significant price reductions, while 10 of them also showed significant increases in both volumes and expenditures. Conclusions: China’s NVBP policy exclusively for insulin significantly reduced prices, increased overall volumes and lowered expenditures. These changes indicate that this policy enhances insulin utilisation and affordability, providing evidence for centralised procurement’s effectiveness in mitigating diabetes-related economic burden.

1 April 2026 in BMJ Public Health
Verified
Journal Article
Open access
LZLirong Zhang
Lirong Zhang
HYHongbin Yi
Hongbin Yi
LKLiping Kuai
Liping Kuai
SHSheng Han
Sheng Han
HSHong Sun
Hong Sun
XWXiaoxia Wei
Xiaoxia Wei
Introduction: To evaluate the associations between approval approaches and the Chinese Society of Clinical Oncology (CSCO) guidelines for haematological cancer drug indications. Methods: Haematological cancer drug indications approved via different approaches between 2015 and 2023 were retrieved from the National Medical Products Administration (NMPA) website, and their CSCO guideline recommendation levels were analysed. Basic characteristics were analysed descriptively. Fisher’s test and t-tests were used to respectively explore the associations of the approval approaches and the recommendation level, and the time difference between the indications obtaining the recommendation level and being approved by the NMPA. Changes in recommendation levels were also analysed. Results: The NMPA approved 52 haematological cancer drug indications (33 anticancer drugs) from 2015 to 2023. 5 indications were approved via routine approval (RA) and 47 were approved via accelerated approval (AA). 39 indications obtained CSCO guideline recommendation level I. Indications approved via the AA and RA were similarly likely to obtain level I. The average time for the indications approved via the RA to obtain the recommendation level is 7.6 months before the indications were approved by the NMPA. And the average time for the indications approved via AA to obtain the recommended level is −5.51 months. For indications approved via priority review and RA, there was a difference in the average time from obtaining recommendation level to obtaining NMPA approval. Compared with CSCO’s initial recommendation levels, 15 indications obtained higher recommendation level in the updated CSCO guideline. Conclusions: Most haematological cancer drug indications obtained CSCO guideline recommendation level I, with no significant difference between AA and RA in the recommendation level. Indications approved via RA obtained recommendation level more quickly. Some indications obtained a higher recommendation level in the updated guideline. Strengthening communication between the NMPA and CSCO and ensuring timely integration of emerging evidence may improve the alignment between approval decisions and recommendation level.